Category: duke retractions

Two mega-corrections for Anil Potti in the Journal of Clinical Oncology

Anil Potti can add two corrections to his less-and-less impressive publication record. The mega-corrections — part of what we are close to being ready to call a trend in errata notices — in the Journal of Clinical Oncology (JCO) are, however, quite impressive, each with at least a dozen points.

One of the corrections, for a paper cited 15 times, according to Thomson Scientific’s Web of Knowledge, basically removes all references to chemotherapy sensitivity: Continue reading Two mega-corrections for Anil Potti in the Journal of Clinical Oncology

Anil Potti and colleagues retract ninth paper, this one in JCO

Former Duke oncology researcher Anil Potti has retracted another paper, marking his ninth withdrawal. The notice in the Journal of Clinical Oncology (JCO) reads:

“An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer” by Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, and Johnathan M. Lancaster (J Clin Oncol 25:517-525, 2007)

The majority of the authors wish to retract this article because Continue reading Anil Potti and colleagues retract ninth paper, this one in JCO

Potti and colleagues retract 2008 JAMA paper

Anil Potti‘s retraction count is now eight with the withdrawal of a 2008 study in the Journal of the American Medical Association (JAMA).

Here’s the notice, which appeared online in JAMA sometime yesterday: Continue reading Potti and colleagues retract 2008 JAMA paper

New in PNAS: Potti retraction number seven, and a Potti correction

The Proceedings of the National Academy of Sciences (PNAS) has published the seventh retraction for former Duke researcher Anil Potti, who now faces a lawsuit in the midst of an ongoing investigation into his work:

Retraction for “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities,” by Katherine S. Garman, Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, Anna Mae Diehl, Dawn Provenzale, Geoffrey S. Ginsburg, B. Michael Ghadimi, Thomas Ried, Joseph R. Nevins, Sayan Mukherjee, David Hsu, and Anil Potti, which appeared in issue 49, December 9, 2008, of Proc Natl Acad Sci USA (105:19432–19437; first published December 2, 2008; 10.1073/pnas.0806674105).

The authors wish to note the following: “We wish to retract this article because we have been unable to reproduce certain key experiments described in the paper regarding validation and use of the colon cancer prognostic signature. This includes the validation performed with dataset E-MEXP-1224, as reported in Fig. 2A, as well as the generation of prognostic scores for colon cancer cell lines, as reported in Fig. 4. Because these results are fundamental to the conclusions of the paper, the authors formally retract the paper. We deeply regret the impact of this action on the work of other investigators.”

The 2008 paper, which has been cited 27 times, according to Thomson Scientific’s Web of Knowledge, was already the subject of a minor 2009 correction: Continue reading New in PNAS: Potti retraction number seven, and a Potti correction

Potti retraction tally grows to six with a withdrawal in PLoS ONE, and will likely end up near a dozen

Anil Potti and his former Duke colleagues have retracted a sixth paper, this one in PLoS ONE.

According to the retraction notice for “An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer,” the withdrawal was prompted by the retraction of a Nature Medicine paper that formed the basis of the PLoS ONE study’s approach: Continue reading Potti retraction tally grows to six with a withdrawal in PLoS ONE, and will likely end up near a dozen

Duke sued over Potti case

Anil Potti, courtesy Duke

From the “not terribly surprising” department: Eight patients — or their estates — who enrolled in clinical trials at Duke overseen by Anil Potti and colleagues have sued the university.

The 90-page lawsuit, which names Duke, Potti, Potti’s boss Joseph Nevins, CancerGuide Diagnostics (in which Potti and Nevins had an interest), among others, does a thorough job of documenting the case. In particular, it reviews the history of the trials, which were stopped in 2009, restarted, and then stopped for good as more and more issues came to light. It emphasizes, as you would expect, that Duke and the Potti team were warned repeatedly about problems in their work, notably by Keith Baggerly and a colleague.

Potti and colleagues have, as Retraction Watch readers will remember, now retracted five papers.

The plaintiff’s attorney, Thomas Henson, told Raleigh-Durham’s ABC11: Continue reading Duke sued over Potti case

Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers

Anil Potti, the former cancer researcher whose work has become the subject of intense scrutiny that has already led to the retraction of five papers, didn’t tell the Journal of the American Medical Association (JAMA) about two very relevant corporate relationships he had when he published papers there, Retraction Watch has learned.

JAMA has published two papers by Potti and colleagues: 2008’s “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” and 2010’s “Age- and Sex-Specific Genomic Profiles in Non-Small Cell Lung Cancer.”

The Cancer Letter, which has been way out front in the Potti case, first reported Potti’s relationships with Eli Lilly and CancerGuide Diagnostics (formerly Oncogenomics, Inc.). As The Chronicle, Duke’s student newspaper, reported last September, the two companies cut their ties with Potti in July 2010 after allegations of misconduct and lying about a Rhodes Scholarship came to light.

But that was after the two papers were published, and Potti had relationships with both since 2006. As The Chronicle notes, he was a director at CancerGuide Diagnostics (formerly Oncogenomics, Inc.), and Continue reading Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers

A fifth retraction for Anil Potti, this one in Blood

courtesy Duke

The list of papers retracted by former Duke oncologist Anil Potti has grown to five. The notice, from Blood: Continue reading A fifth retraction for Anil Potti, this one in Blood

Ties that don’t bind: Group retracts parathyroid hormone crystallography paper

The authors of a 2008 paper alleging to have described how a particular protein binds to the parathyroid hormone have retracted it. The paper, “Structure of the Parathyroid Hormone Receptor C Terminus Bound to the G-Protein Dimer Gβ12,” has been cited 12 times, according to Thomson Scientific’s Web of Knowledge. According to the notice: Continue reading Ties that don’t bind: Group retracts parathyroid hormone crystallography paper

Anil Potti resurfaces at South Carolina cancer center

courtesy Duke

Anil Potti, the oncologist who has been forced to retract four papers because of results that could not be reproduced, and resigned last fall from Duke, has a new job. He’s joined the Coastal Cancer Center, an oncology practice with four offices in South Carolina and one in North Carolina.

The Duke Fact Checker was apparently the first to report the news. The Cancer Letter, which has been out front on the Potti story for a year, first reported the news.*

It’s not surprising that Potti’s Coastal Center bio leaves out any mention of his troubled research and the fact that he faked a Rhodes scholarship on a grant application. Investigations into what happened at Duke are ongoing. Continue reading Anil Potti resurfaces at South Carolina cancer center